AEGiS-SC: Oakland AIDS Activist's Latest Crusade Jeff Getty fighting for interspecies grafts -- he got baboon marrow San Francisco ChronicleImportant note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Click here to return to San Francisco Chronicle main menu
DonateNow


Oakland AIDS Activist's Latest Crusade Jeff Getty fighting for interspecies grafts -- he got baboon marrow

San Francisco Chronicle; Monday, February 16, 1998
Charles Petit, Chronicle Science Writer


Two years after receiving a baboon bone marrow transplant, Oakland resident and AIDS activist Jeff Getty is seeing his health start to deteriorate again -- but not enough to stop him from pinning a new label on himself: Xeno-activist.

That's xeno as in xenografts and xenotransplants, the surgical transfer of organs between species -- particularly animals to people. With science moving closer to being able to put not only animal bone marrow but pig hearts, kidneys and livers into people, debate is picking up on whether such practices might endanger the general population.

Getty, 40, was in Philadelphia on Saturday to take part in a symposium on medical prospects for xenografts during the annual meeting of the American Association for the Advancement of Science. There is no federal moratorium on transplants from animals to people, and a recent review by the Public Health Service endorsed further, well-monitored research into it. But some authorities fear that wide use of animal organs could introduce new viruses or other microbes into people where they would mutate into forms highly infectious to humans, possibly spawning epidemics against which modern medicine and natural human immunology would have few defenses.

Getty's position is firm. To him, to tell somebody that he is going to die unless he gets a pig liver but that he cannot get one "because some day it could start a pig disease epidemic, so he must die -- that is unethical."

The session was organized by Dr. Suzanne Ildstad of Philadelphia's Allegheny University of the Health Sciences. She designed the baboon transplant performed on Getty on Dec. 14, 1995, at San Francisco General Hospital with participation by University of California at San Francisco doctors.

Getty, who was then moving into advanced AIDS, got an injection of baboon bone marrow. The hope was that the marrow might colonize his own bones and eventually create a population of immune cells in his system that would not be not affected by the human immunodeficiency virus, or HIV, which causes AIDS.

Although the baboon cells disappeared to below detectable levels within a few weeks of the injection, Getty's health improved considerably -- possibly due to the radiation and other treatments Getty got at the same time.

"I had been at death's door," he said. "But I got one pretty good year out of it."

In recent months, however, Getty's immune system has again fallen to a low ebb, the viral load in his blood is rising, and sinus and asthma-like breathing difficulties are returning. He keeps his weight up with the help of human growth hormone and anabolic steroids, and is taking several experimental medications to slow the virus' attack.

For the time being, Ildstad has suspended experiments with baboon or any other kind of transplants to treat AIDS. Her concern is not safety -- but in finding a way to help the grafts take hold. She wants to do additional basic research before trying it again, perhaps in a few years.

In the meantime, Getty said his experience has turned him into a crusader for animal-to-human transplants. His goal is to break down what he says are psychological and irrational fears on the part of many people. "I'm the first," he said, "but watch out, there are more coming."

Ildstad said at the conference that for some illnesses, animal organs appear to provide the only hope. About half of heart transplant candidates die because no suitable donor can be found.

"The donor pool is maxed out," she said. "The doctors are asking (relatives of potential donors who have died or are dying), but people are saying no."

While no method exists to prevent a whole animal organ, such as a heart or kidney, from being rejected, research programs into xenotransplantation have already shown how to increase success rates of human-to-human transplants between people who are not good genetic matches, she said. In five to ten years, she said, the extensive publicity campaigns that some patients or their supporters undertake now to find suitable blood marrow or other donors will become a thing of the past.


980216
SC980205


Copyright © 1998 - San Francisco Chronicle Press. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Chronicle, Permissions Desk, 901 Mission Street, San Franciso, CA 94103. You may also send a fax to (415) 495-3843, or an email message to chronperm@sfgate.com.   http://www.sfgate.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .